The complaint centers on allegations that GeneDx made false or misleading statements concerning the integration of Fabric into its core business. While the company publicly touted potential cost reductions and efficiency gains through optimized algorithms and improved dry lab processes, the lawsuit claims these assertions lacked a reasonable factual basis. According to the filing, defendants either knew of or recklessly disregarded significant issues regarding Fabric's business health, which ultimately harmed GeneDx operations.

These allegedly inflated statements kept stock prices artificially high throughout the class period, causing financial losses for shareholders once the reality of the situation surfaced. The Gross Law Firm is now seeking to represent those affected, with a deadline of August 3, 2026, for investors to apply for lead plaintiff status. Participation in the action does not require immediate lead plaintiff appointment, and the firm offers portfolio monitoring for those who register their losses.